Frontotemporal Degeneration Clinical Trial
Official title:
A Phase I Clinical Trial, Using Interleukin-2 (IL-2) and Abatacept in Patients With Frontotemporal Disorders
Neuroinflammation is a significant component of Frontotemporal Disorder (FTD). Our preliminary unpublished data demonstrated that regulatory T cells (Tregs) have a compromised phenotype and reduced suppressive function in FTD patients, skewing the immune system toward a proinflammatory status and potentially contributing to disease progression. Low dose interleukin-2 (IL-2) is now viewed as a very promising immunoregulatory drug with the capacity to selectively expand and restore functional Tregs. Our preclinical data also demonstrated synergistic effect of interleukin-2 and abatacept (CTLA4-IgG) in remodeling immunologic pathways. Abatacept is an FDA approved medication that has been indicated as a monotherapy or concomitantly with other anti-inflammatory drugs to modulate inflammation in autoimmune disorders. This study is a phase I, open-label study to assess safety and tolerability of low dose IL-2 plus abatacept immunotherapy in FTD individuals. In the first part of this study, 5 FTD patients will be recruited. These five individuals will receive subcutaneous abatacept (125 mg) followed by five-day-courses of IL-2 (1MUI/day) every four weeks for a total of 21 weeks (part-1 of the study). If the treatment strategy is safe and well-tolerated, up to 5 additional FTD subjects will be recruited to receive subcutaneous abatacept (125 mg) followed by five-day-courses of IL-2 (1MUI/day) every two weeks for a total of 21 weeks (part 2 of the study).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05204017 -
Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS
|
||
Recruiting |
NCT06337578 -
Advances in Telephone-based Cognitive Screening Procedures
|
||
Recruiting |
NCT03174938 -
The Swedish BioFINDER 2 Study
|
N/A | |
Active, not recruiting |
NCT05524181 -
Telehealth-enabled Integrated Palliative Care for People With Dementia
|
N/A | |
Enrolling by invitation |
NCT04060082 -
Voices Of Individuals: Challenges and Experiences Of bvFTD
|
||
Completed |
NCT03452956 -
Cognitive Impairement In Frontotemporal Dementia
|
||
Recruiting |
NCT01147679 -
Study of Social Behavior and Emotion in Frontotemporal Dementia, Alzheimer's Disease and Controls
|
N/A | |
Recruiting |
NCT06120361 -
The Swedish BioFINDER - Primary Care Study
|
||
Recruiting |
NCT06122415 -
The Swedish BioFINDER - Memory Clinic Study
|
||
Recruiting |
NCT05384353 -
In Vivo PET of Synaptic Density in Cognitive Disorders
|
||
Recruiting |
NCT05317871 -
Clearance Mechanisms in Atypical Neurodegenerative Diseases
|